Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Anupam Rasayan becomes first company to commercialise ETFA, eyes $500 million market
Anupam Rasayan said it will continue to invest in advanced process technologies, research capabilities and sustainable manufacturing practices as part of its long-term growth strategy.
CRISIL places Anupam Rasayan's credit ratings on watch
The ratings have been placed on watch following announcement by ARIL of acquisition of 43.3-48.2% equity stake in Bliss GVS Pharma, a pharmaceutical (pharma) formulations company based in India, which may be funded through debt, equity or internal accrual.
Anupam Rasayan to acquire up to 43 pc stake in Bliss GVS Pharma for around Rs 1,369 cr
Specialty chemicals maker Anupam Rasayan India is set to acquire up to 43.3% of Bliss GVS Pharma for an estimated Rs 1,369.51 crore, with an open offer for an additional 26%. This strategic move aims to strengthen Anupam Rasayan's presence across the pharmaceutical value chain, from key starting materials to finished dosage formulations.
Anupam Rasayan enters formulations business with ₹1,369 cr Bliss GVS Pharma acquisition
Anupam Rasayan will acquire up to 74.2% stake in Bliss GVS Pharma, strengthening its presence across the pharmaceutical value chain and expanding its reach in regulated global markets.
Anupam Rasayan completes USD150-mln acquisition of US speciality chemical maker Jayhawk
Anupam Rasayan India has acquired US-based Jayhawk Fine Chemicals Corporation for approximately USD 150 million. This strategic move aims to broaden Anupam Rasayan's global presence and access new end-use markets. The acquisition is expected to enhance its integrated platform and create cross-selling opportunities. Jayhawk's operations in performance materials will now be consolidated into Anupam Rasayan's financials.